Description: Letairis is an endothelin receptor antagonist selective for the endothelin type-A (ETA) receptor. This prevents the action of a potent paracrine peptide on the ETA receptor which leads to vasodilation.


Dosing: 5mg once daily, up to maximum of 10 mg daily

How Supplied: Tablets 5mg and 10mg

Contraindications/Warnings: Contraindicated in pregnancy; avoid grapefruit

Major Adverse Reactions: Pulmonary edema with pulmonary veno-occlusive disease (PVOD); decreased sperm count; decreased hemoglobin; fluid retention

Major Drug Interactions: Use caution with other vasodilators

REFERENCES


4. Letairis (ambrisentan) [package insert]. Foster City, CA: Gilead; May 2014


**Revision History:**
Date Approved by P&T Committee: 10/28/14; QAC 11/25/14
Date Reviewed/No Updates: 01.13.15 by C. Sanders, MD
Date Approved by P&T Committee: 01.27.15
Date Reviewed/No Updates: 01.26.16 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 01.26.16
Date Reviewed/No Updates: 01.24.17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 01.24.17

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>